Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

National Comprehensive Cancer Network. Non-small cell lung cancer, version 6. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 29, 2020. Zappa, 2016, Non-small cell lung cancer: current treatment and future advances, Transl Lung Cancer Res, 5, 288, 10.21037/tlcr.2016.06.07 Dagogo-Jack, 2020, Personalized diagnostic workflows: the next wave of precision medicine in NSCLC, J Thorac Oncol, 15, 888, 10.1016/j.jtho.2020.03.019 Arbour, 2019, Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review, JAMA, 322, 764, 10.1001/jama.2019.11058 Tsang, 2019, Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer, Cold Spring Harb Mol Case Stud, 5, a002659, 10.1101/mcs.a002659 O’Leary, 2019, Targeting BRAF mutations in non-small cell lung cancer, Transl Lung Cancer Res, 8, 1119, 10.21037/tlcr.2019.10.22 Planchard, 2016, Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol, 17, 984, 10.1016/S1470-2045(16)30146-2 Planchard, 2017, Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial, Lancet Oncol, 18, 1307, 10.1016/S1470-2045(17)30679-4 Santarpia, 2012, Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy, Expert Opin Ther Targets, 16, 103, 10.1517/14728222.2011.645805 Amaral, 2017, MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition, Eur J Cancer, 73, 93, 10.1016/j.ejca.2016.12.012 Rudin, 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non–small-cell lung cancer, J Thorac Oncol, 8, e41, 10.1097/JTO.0b013e31828bb1b3 Cardarella, 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer, Clin Cancer Res, 19, 4532, 10.1158/1078-0432.CCR-13-0657 Marchetti, 2011, Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations, J Clin Oncol, 29, 3574, 10.1200/JCO.2011.35.9638 Planchard, 2016, Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 642, 10.1016/S1470-2045(16)00077-2 Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 Schadendorf, 2017, Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, Eur J Cancer, 82, 45, 10.1016/j.ejca.2017.05.033 Robert, 2019, Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma, N Engl J Med, 381, 626, 10.1056/NEJMoa1904059 Planchard, 2020, Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC), J Clin Oncol, 38 Oncomine Dx Target Test—the right choice for your patients. The Personalized Medicine Report by PMC (Personalized Medicine Coalition, 2017). 2017. https://personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The-Personalized-Medicine-Report1.pdf. Accessed June 29, 2020. Eroglu, 2016, Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy, Ther Adv Med Oncol, 8, 48, 10.1177/1758834015616934 Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 Mossé, 2016, Anaplastic lymphoma kinase as a cancer target in pediatric malignancies, Clin Cancer Res, 22, 546, 10.1158/1078-0432.CCR-14-1100 Khan, 2018, ALK inhibitors in the treatment of ALK positive NSCLC, Front Oncol, 8, 557, 10.3389/fonc.2018.00557 2018 2018 2018 Calles, 2020, Checkpoint blockade in lung cancer with driver mutation: choose the road wisely, Am Soc Clin Oncol Educ Book, 40, 372, 10.1200/EDBK_280795 Pennell, 2019, Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices, Am Soc Clin Oncol Educ Book, 39, 531, 10.1200/EDBK_237863 Hanna, 2021, Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update, J Clin Oncol, 39, 1040, 10.1200/JCO.20.03570 Planchard, 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, iv192, 10.1093/annonc/mdy275 Dudnik, 2018, BRAF mutant lung cancer: programmed death ligand 1 expression. Tumor mutational burden, microsatellite instability status, and response to immune check point inhibitors, J Thorac Oncol, 13, 1128, 10.1016/j.jtho.2018.04.024 Mazieres, 2019, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry, Ann Oncol, 30, 1321, 10.1093/annonc/mdz167 Offin, 2019, P1.04-39 molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers, J Thorac Oncol, 14, S455, 10.1016/j.jtho.2019.08.942 Rihawi, 2019, BRAF mutant NSCLC and immune checkpoint inhibitors: results from a real-world experience, J Thorac Oncol, 14, e57, 10.1016/j.jtho.2018.11.036 Guisier, 2020, Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018, J Thorac Oncol, 15, 628, 10.1016/j.jtho.2019.12.129 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Wu, 2017, Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial, Lancet Oncol, 18, 1454, 10.1016/S1470-2045(17)30608-3 Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, 389, 917, 10.1016/S0140-6736(17)30123-X Ma, 2020, Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens, Pathol Res Pract, 216, 153036, 10.1016/j.prp.2020.153036 Matsumoto, 2020, Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia, J Clin Oncol, 38 Ortiz-Cuaran, 2020, Circulating tumor DNA genomics reveal potential mechanisms of resistance to BRAF-targeted therapies in patients with BRAF-mutant metastatic non-small cell lung cancer, Clin Cancer Res, 26, 6242, 10.1158/1078-0432.CCR-20-1037 Blakely, 2017, Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers, Nat Genet, 49, 1693, 10.1038/ng.3990 Hennessy, 2005, Exploiting the PI3K/AKT pathway for cancer drug discovery, Nat Rev Drug Discov, 4, 988, 10.1038/nrd1902 Aisner, 2018, The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations—the lung cancer mutation consortium (LCMC2), Clin Cancer Res, 24, 1038, 10.1158/1078-0432.CCR-17-2289